Singapore Infectious Disease Clinical Research Network

Singapore Infectious Disease Clinical Research Network

The Singapore Infectious Disease Clinical Research Network (SCRN) was established in 2013 and is funded by the Ministry of Health with the aim of conducting multi-centre clinical studies. SCRN is hosted by the National Centre for Infectious Diseases (NCID) and is a network of physicians at all of Singapore's public hospitals who conduct clinical research related to infectious diseases.

We collaborate with primary care providers, academia, industry and international partners with the aim of conducting high quality research. SCRN also works closely with the Programme for Research in Epidemic Preparedness and Response (PREPARE) to ensure the network is ready and capable of conducting clinical research in response to an infectious disease threat. We support young and junior investigators in their journey to develop experience and expertise in clinical and collaborative infectious disease research.

Mission	Vision
To lead high-quality infectious disease clinical research from Singapore	To be a collaborative infectious disease research network connecting public healthcare, academia and industry in Singapore To be a professional, multidisciplinary team working together to support clinician-investigators to perform clinically relevant and practice-oriented research To be prepared to rapidly respond to support outbreak research of national importance To form a sustainable platform for controlled human infection studies

Mission

Vision

To lead high-quality infectious disease clinical research from Singapore

To be a collaborative infectious disease research network connecting public healthcare, academia and industry in Singapore
To be a professional, multidisciplinary team working together to support clinician-investigators to perform clinically relevant and practice-oriented research
To be prepared to rapidly respond to support outbreak research of national importance
To form a sustainable platform for controlled human infection studies

Services

Executive Committee

Partners

Executive Committee

SCRN is overseen by an executive committee with representative from every public hospital in Singapore to engage local infectious disease physicians, microbiologists and scientists in a collaborative approach to spearhead cross-institutional clinical research in Singapore. In addition, head of SCRN leads a team that supports SCRN with administrative matters and coordinate clinical studies. It comprises research fellows, manager, executive, and a team of clinical research coordinators who are certified in Good Clinical Practice (GCP).

Associate Professor Barnaby Young

Senior Consultant, Department of Infectious Diseases, NCID
(Head of SCRN)

Assistant Professor Shirin Kalimuddin

Senior Consultant,
Department of Infectious Diseases, SGH

Professor David Lye Chien Boon

Senior Consultant, Department of Infectious Diseases, NCID

Associate Professor Yi Ann Louis Chai

Senior Consultant, Division of Infectious Diseases, NUH

Dr Li Jia Hui

Head and Consultant, Infectious Diseases, KKH

Dr Tan Seow Yen

Consultant, Department of Infectious Diseases, CGH

Dr Louisa Sun

Consultant, Infectious Diseases, AH

Dr Ooi Say Tat

Senior Consultant, Division of Infectious Diseases, KTPH

Adjunct Assistant Professor
Surinder Kaur M S Pada

Head of Division & Senior Consultant, Division of Infectious Diseases, NTFGH

Dr Zheng Shu Wei

Consultant, Department of Infectious Disease, SKH

Dr Ray Lin Junhao

Head and Consultant, Infectious Diseases, WH

SCRN partners include:

Advancing Clinical Evidence in Infectious Diseases (ADVANCE-ID)
Australasian Society for Infectious Diseases (ASID)
Coalition for Epidemic Preparedness Innovations (CEPI)
Imperial College London
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC)
National Institutes of Health (NIH)
Programme for Research in Epidemic Preparedness and Response (PREPARE)
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
Staphylococcus aureus Network Adaptive Platform (SNAP)
VACCELERATE
World Health Organization (WHO)

Learn More About Our Clinical Studies

Milestones

Sing-CoV

SNAP

INVEST

I3D-RESPIRO

As of December 2023, SCRN has received $24.6M to facilitate 68 studies which enrolled over 7,800 participants.

Singapore's first human challenge study 'The Singapore Platform for Controlled Human Infections with SARS-CoV-2', also known as Sing-CoV, aims to conduct a safe SARS-CoV-2 Delta variant human infection challenge in adult volunteers to investigate factors associated with susceptibility to and protection from infection, and to facilitate the development of vaccines, antivirals, and other interventions.

Study objectives are:

Establish a SARS-CoV-2 controlled human infection (CHI) model in previously vaccinated, seropositive volunteers in Singapore, with an infection rate of up to 70%.
Characterise the clinical, virological and immunological responses following controlled inoculation of Delta variant SARS-CoV-2 in Singapore volunteers.
Identify determinants of breakthrough infection and correlates of protection in individuals with pre-existing immunity.
Explore antigenic imprinting and the effects of pre-existing immunity on response to infection with an immune escape variant.
Examine time-course of the generation of respiratory aerosols containing infectious virus from inoculation onwards.

Recruitment starts in June-2024.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.sg.

International adaptive platform trial 'Staphylococcus aureus Network Adaptive Platform' also known as SNAP, aims to find out which of the antibiotics currently in use work best to treat patients with Staphylococcus aureus bacteraemia (SAB).

SAB is a common and severe bloodstream infection with a 90-day mortality of 15-30% despite current best available therapies. Staphylococcus aureus is a type of bacteria that can grouped into three types depending on their antibiotic sensitivity profile: penicillin-susceptible S. aureus (PSSA), methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The objective of SNAP is to identify the effect of a range of clinical interventions on all-cause 90-day mortality.

This study is currently recruiting.

For further information on SNAP trial, please click here.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.sg.

International, multicentre, randomised controlled trial- ‘Early oral step-down antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia’, also known as INVEST, aims to determine whether oral antibiotics are as effective and safe compared with intravenous antibiotics in treating uncomplicated bloodstream infections by Gram-negative bacteria.

The incidence of Gram-negative bacteraemia is rising globally, and remains a major cause of morbidity and mortality for hospitalised patients. Although practice guidelines provide general recommendations for treatment duration for Gram-negative bacteraemia, the optimal route of administration is yet to be definitively defined. The majority of patients with Gram-negative bacteraemia initially receive intravenous (IV) antibiotic therapy. Compared with IV therapy, oral therapy eliminates the risk of catheter-associated adverse events, enhances patient quality of life, and reduces total healthcare costs.

This study is currently recruiting.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.sg.

Multicentre, observational prospective study ‘Infectious Diseases Consortium for Study on Integrated and Innovative Approaches for Management of Respiratory Infections: Respiratory Infections Research and Outcome study’, also known as I3D-RESPIRO, aims to evaluate the causes and outcomes of moderate-to-severe Community Acquired Pneumonia in Singapore and the surrounding region, so as to facilitate development of new strategies to diagnose and treat them.

Study objectives are:

Describe the clinical features of the illness or syndrome and identify risk factors for severe disease
Describe the response to treatment, including supportive care and novel therapeutics
Observe pathogen replication, excretion and evolution within the host, and identify possible determinants of severity and transmission using high-throughput sequencing of pathogen genomes obtained from the respiratory tract, blood, urine, stool and other biological samples
Characterise the host responses to infection and therapy over time, including innate and acquired immune responses, circulating levels of immune signalling molecules and gene expression profiling in peripheral blood
Identify host genetic variants associated with disease progression or severity
Understand transmissibility and the probabilities of different clinical outcomes following exposure and infection

The study is currently recruiting.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.sg.

Loading component...

Loading component...